Eliquis apixaban

Cost-driven discontinuation is the single largest adherence threat: patients are stopping Eliquis mid-therapy because they cannot afford it, creating exactly the thrombotic rebound risk the boxed warning flags.

• Fatigue, muscle weakness, and joint pain are the dominant patient-reported complaints, yet clinicians routinely dismiss them as unrelated, deepening distrust and fueling self-discontinuation.
• Affordability is a crisis-level driver: uninsured or underinsured patients report lapses of months due to out-of-pocket costs exceeding $500 per month, with some returning to warfarin or stopping anticoagulation altogether.
• Patients who tolerate Eliquis well become its strongest advocates, emphasizing freedom from INR monitoring and dietary restrictions as quality-of-life wins over warfarin or Xarelto.
• An emerging cluster of questions about blood sugar elevation, weight changes, and GLP-1 co-prescription signals a growing polypharmacy population requiring targeted education and monitoring guidance.